News

Video

Phase 3 Study (PIVOTAL) of Neoadjuvant Intralesional Daromun vs. Immediate Surgery in Fully Resectable Melanoma With Regional Skin and/or Nodal Metastases

Author(s):

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein

PIVOTAL (NCT02938299) is an open label, randomized, multicenter, phase 3 trial evaluating Daromun as a neoadjuvant intralesional therapy for resectable, locally advanced Stage III melanoma.

Related Videos
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study
Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial
Results From the Phase 1 Study of the Novel BCL2 Inhibitor Sonrotoclax in Combination with Zanubrutinib for Relapsed/Refractory CLL/SLL Show Deep and Durable Responses
Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Related Content
FDA
September 5th 2024

FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Mai-Britt Zocca, PhD, president, chief executive officer, IO Biotech
September 4th 2024

Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Revisit Every OncLive On Air Episode From August 2024
August 30th 2024

Revisit Every OncLive On Air Episode From August 2024

Marjorie Green, MD
August 29th 2024

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC